Stockreport

C2N Diagnostics Says FDA's Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer's Disease Pathology [Yahoo! Finance]

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF Food and Drug Administration to approve donanemab for treatment of early Alzheimer's disease. Researchers used C2N's Precivity-p-tau217 blood biomarker in its Phase 3 cl [Read more]